Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Dose-ranging, Open-label, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of Palonosetron HCl Buccal Film Versus IV Palonosetron 0.25 mg for the Prevention of CINV in Cancer Patients Receiving MEC

NCT04592198 is registered in ClinicalTrials.gov with Xiamen LP Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT04592198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04592198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Dose-ranging, Open-label, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of Palonosetron HCl Buccal Film Versus IV Palonosetron 0.25 mg for the Prevention of CINV in Cancer Patients Receiving MEC
Lead sponsor
Xiamen LP Pharmaceutical Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2020
Completion date
March 25, 2021
Enrollment
22 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

nausea with vomiting chemotherapy-induced